HealthLinx Restarts Sales of OvPlex Ovarian Cancer Test, Launches 1,150-Patient International Trial

The trial will study samples from 1,150 patients in Australia and the UK to explore the utility of adding two protein biomarkers to the test to improve its sensitivity and specificity, Nick Gatsios, HealthLinx managing director, told ProteoMonitor.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.